COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022.

COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022.

Publication date: Jan 21, 2024

Epidemiologic studies on coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (pwMS) have focused on the first waves of the pandemic until early 2021. We aimed to extend these data from the onset of the pandemic to the global coverage by vaccination in summer 2022. This retrospective, multicenter observational study analyzed COVISEP registry data on reported COVID-19 cases in pwMS between January 2020 and July 2022. Severe COVID-19 was defined as hospitalization or higher severity. Among 2584 pwMS with confirmed/highly suspected COVID-19, severe infection rates declined from 14. 6% preomicron wave to 5. 7% during omicron wave (p 

Concepts Keywords
Coronavirus COVID-19
Hospitalization COVID-19 testing
July COVID-19 vaccines
Pandemic Multiple sclerosis
SARS-CoV-2
vaccination

Semantics

Type Source Name
disease MESH COVID-19
disease MESH multiple sclerosis
disease VO vaccination
disease MESH infection
disease MESH Long Covid

Original Article

(Visited 1 times, 1 visits today)